Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Februar 2021 15:45 ET | Quelle: The Rosen Law Firm PA

BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA

NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma...
17. Dezember 2020 18:17 ET | Quelle: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Sonoma...
02. Dezember 2020 09:25 ET | Quelle: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma...
30. November 2020 21:00 ET | Quelle: Bragar Eagel & Squire

SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals,...
05. Juni 2017 16:05 ET | Quelle: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017

Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology salesCash position of $17.5 million; management believes the...